|Bid||0.00 x 1000|
|Ask||0.00 x 1000|
|Day's Range||4.83 - 5.19|
|52 Week Range||2.10 - 7.00|
|Beta (3Y Monthly)||1.62|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Chris Xu has been the CEO of Cesca Therapeutics Inc. (NASDAQ:KOOL) since 2016. First, this article will compare CEO...
We highlight five small-cap ETFs and stocks that have outperformed in September. These could be excellent plays for investors should the same trends prevail.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. ACADIA Pharmaceuticals (NASDAQ: ACAD ) shares ...
Cesca Therapeutics Inc. (NASDAQ:KOOL) shareholders should be happy to see the share price up 13% in the last month...
Cesca Therapeutics (NASDAQ: KOOL ) shares spiked higher after the company's subsidiary, ThermoGenesis, received Health Canada approval for its AXP II System for cord blood processing. "Health Canada's ...
If you're interested in Cesca Therapeutics Inc. (NASDAQ:KOOL), then you might want to consider its beta (a measure of...
Cesca Therapeutics (KOOL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.